Ankylosing Spondylitis Pipeline and Clinical Trials Analysis 2025: Medication, EMA, PDMA, FDA Approvals, Therapies, ROA, MOA, NDA Approval and Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Ankylosing Spondylitis pipeline constitutes 20+ key companies continuously working towards developing 20+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Ankylosing Spondylitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ankylosing Spondylitis Market.

The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details

Request for sample report @ https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Ankylosing Spondylitis Pipeline Report:
• Ankylosing Spondylitis Companies across the globe are diligently working toward developing novel Ankylosing Spondylitis treatment therapies with a considerable amount of success over the years.
• Ankylosing Spondylitis companies working in the treatment market are Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cadilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others are developing therapies for the Ankylosing Spondylitis treatment
• Emerging Ankylosing Spondylitis therapies in the different phases of clinical trials are- KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others are expected to have a significant impact on the Ankylosing Spondylitis market in the coming years.
• In April 2025, Novartis announced a Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea
• In December 2024, Suzhou Zelgen Biopharmaceuticals Co.,Ltd announced a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Jaktinib in Subjects With Active Ankylosing Spondylitis (AS)
• UCB Biopharma: On November 14, 2024, UCB Biopharma presented new two-year data for Bimekizumab (bimekizumab-bkzx) at the American College of Rheumatology (ACR) Convergence 2024, showing sustained improvements in clinical and patient-reported outcomes for Ankylosing Spondylitis.
• In September 2024, UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS).1 BIMZELX is the first approved treatment for these three indications that is designed to selectively inhibit two key cytokines driving inflammatory processes - interleukin 17A (IL-17A) and interleukin 17F (IL-17F).1 These newly approved indications follow the first U.S. approval for BIMZELX in October 2023 for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
• In April 2024, Akeso announced a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with active ankylosing spondylitis.
• MoonLake Immunotherapeutics: MoonLake Immunotherapeutics is actively working on Phase 3 clinical trials for their lead candidate, belimumab, with updates reported as of April 2024.
• Qyuns Therapeutics: Qyuns Therapeutics is involved in the development of novel small molecule inhibitors for Ankylosing Spondylitis, with updates reported as of April 2024.
• Jiangsu HengRui MedicIne: Jiangsu HengRui MedicIne is developing new therapeutic options for Ankylosing Spondylitis, with updates reported as of April 2024.
• In October 2023, RINVOQ by AbbVie is prescribed for adults with active ankylosing spondylitis who have not responded satisfactorily to conventional therapy.
• In October 2023, In the European Union, bimekizumab has received approval for addressing moderate to severe plaque psoriasis in adults eligible for systemic therapy. It is also approved for treating active psoriatic arthritis and active axSpA in adults, encompassing both non-radiographic axSpA and ankylosing spondylitis, also recognized as radiographic axSpA. Note that labeling information may vary in other approved regions, and it is advisable to refer to local prescribing guidelines. It is crucial to highlight that the efficacy and safety of bimekizumab in HS (Hidradenitis Suppurativa) have not been validated, and regulatory authorities worldwide have not granted approval for its use in this indication.

Ankylosing Spondylitis Overview
Ankylosing Spondylitis is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, leading to pain, stiffness, and reduced mobility. Ankylosing Spondylitis is classified as a type of axial spondyloarthritis and can also impact peripheral joints, eyes, skin, and other organs. Ankylosing Spondylitis typically begins in early adulthood and is more common in males than females.
Ankylosing Spondylitis is strongly associated with the HLA-B27 genetic marker, which plays a key role in disease susceptibility. Ankylosing Spondylitis symptoms include chronic back pain, morning stiffness, fatigue, and in severe cases, spinal fusion. Ankylosing Spondylitis diagnosis involves a combination of clinical evaluation, imaging studies like X-rays or MRI, and genetic testing.
Ankylosing Spondylitis treatment aims to relieve symptoms, maintain posture and flexibility, and slow disease progression. Ankylosing Spondylitis management includes nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologics such as TNF inhibitors and IL-17 inhibitors, and physical therapy. Ankylosing Spondylitis requires long-term monitoring and a multidisciplinary care approach.
Ankylosing Spondylitis research is focused on identifying novel biomarkers, understanding disease mechanisms, and developing more effective targeted therapies. Ankylosing Spondylitis awareness and early intervention are crucial for improving quality of life and preventing long-term complications.

Get a Free Sample PDF Report to know more about Ankylosing Spondylitis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Ankylosing Spondylitis Drugs Under Different Phases of Clinical Development Include:
• KIN-1901: Kinevant Sciences
• Sonelokimab: MoonLake Immunotherapeutics
• QX 002N: Qyuns Therapeutics
• SHR-1314: Suzhou Zelgen Biopharmaceuticals
• SHR0302: Jiangsu HengRui MedicIne
• Jaktinib: Suzhou Zelgen Biopharmaceuticals
• Apremilast: Amgen

Ankylosing Spondylitis Route of Administration
Ankylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical.

Ankylosing Spondylitis Molecule Type
Ankylosing Spondylitis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Ankylosing Spondylitis Pipeline Therapeutics Assessment
• Ankylosing Spondylitis Assessment by Product Type
• Ankylosing Spondylitis By Stage and Product Type
• Ankylosing Spondylitis Assessment by Route of Administration
• Ankylosing Spondylitis By Stage and Route of Administration
• Ankylosing Spondylitis Assessment by Molecule Type
• Ankylosing Spondylitis by Stage and Molecule Type

DelveInsight's Ankylosing Spondylitis Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Ankylosing Spondylitis Market Dynamics
The ankylosing spondylitis (AS) market is influenced by several drivers and barriers. Key drivers include the increasing prevalence of AS, advancements in diagnostic techniques leading to earlier detection, and the development of innovative biologics and targeted therapies enhancing treatment efficacy. Additionally, heightened disease awareness and improved healthcare infrastructure contribute to market expansion. However, barriers such as the high cost of treatment, stringent regulatory requirements, and competition from alternative therapies can impede market growth. Furthermore, the complex nature of AS and potential side effects of therapies may limit patient adherence, posing additional challenges to market progression.

Further Ankylosing Spondylitis product details are provided in the report. Download the Ankylosing Spondylitis pipeline report to learn more about the emerging Ankylosing Spondylitis therapies - https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Ankylosing Spondylitis Therapeutics Market include:
Key companies developing therapies for Ankylosing Spondylitis are - Pfizer (NYSE: PFE), UCB Biopharma (EBR: UCB), Fresenius Kabi (FWB: FRE), Shanghai Henlius Biotech (HKEX: 2696), Fujifilm Kyowa Kirin Biologics (TSE: 4901), Hetero Biopharma (Private), Bio-Thera Solutions (SHA: 688177), Amgen (NASDAQ: AMGN), CinnaGen (Private), Zydus Cadila (NSE: ZYDUSLIFE), Cadila Pharmaceuticals (Private), Sandoz (SWX: SDZ), Innovent Biologics (HKEX: 1801), Torrent Pharmaceuticals (NSE: TORNTPHARM), Cipla (NSE: CIPLA), Emcure Pharmaceuticals (Private), Biogen (NASDAQ: BIIB), Boehringer Ingelheim (Private), Zhejiang Hisun Pharmaceuticals (SHA: 600267), Biocad (Private), AbbVie (NYSE: ABBV), Mycenax Biotech (TPEX: 4726), Celltrion (KRX: 068270), Gilead Sciences (NASDAQ: GILD), Sun Pharma Global (NSE: SUNPHARMA), Jiangsu HengRui Medicine Co., Ltd. (SHA: 600276), Izana Bioscience (Private), Suzhou Zelgen Biopharmaceuticals (SHA: 688266), Iltoo Pharma (Private), Kinevant Sciences (Private), Qyuns Therapeutics (HKEX: 2302), Akeso Biopharma (HKEX: 9926), Nimbus Therapeutics (Private), Enzene Biosciences (Private), Xbrane Biopharma (STO: XBRANE), Dice Molecules (NASDAQ: DICE), and others.

Ankylosing Spondylitis Pipeline Analysis:
The Ankylosing Spondylitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ankylosing Spondylitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ankylosing Spondylitis Treatment.
• Ankylosing Spondylitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ankylosing Spondylitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ankylosing Spondylitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ankylosing Spondylitis drugs and therapies - https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Ankylosing Spondylitis Pipeline Drug Insight
• Coverage: Global
• Key Ankylosing Spondylitis Companies: Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cadilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others.
• Key Ankylosing Spondylitis Therapies: KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others
• Ankylosing Spondylitis Therapeutic Assessment: Ankylosing Spondylitis current marketed and Ankylosing Spondylitis emerging therapies
• Ankylosing Spondylitis Market Dynamics: Ankylosing Spondylitis market drivers and Ankylosing Spondylitis market barriers

Request for Sample PDF Report for Ankylosing Spondylitis Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Ankylosing Spondylitis Report Introduction
2. Ankylosing Spondylitis Executive Summary
3. Ankylosing Spondylitis Overview
4. Ankylosing Spondylitis- Analytical Perspective In-depth Commercial Assessment
5. Ankylosing Spondylitis Pipeline Therapeutics
6. Ankylosing Spondylitis Late Stage Products (Phase II/III)
7. Ankylosing Spondylitis Mid Stage Products (Phase II)
8. Ankylosing Spondylitis Early Stage Products (Phase I)
9. Ankylosing Spondylitis Preclinical Stage Products
10. Ankylosing Spondylitis Therapeutics Assessment
11. Ankylosing Spondylitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ankylosing Spondylitis Key Companies
14. Ankylosing Spondylitis Key Products
15. Ankylosing Spondylitis Unmet Needs
16 . Ankylosing Spondylitis Market Drivers and Barriers
17. Ankylosing Spondylitis Future Perspectives and Conclusion
18. Ankylosing Spondylitis Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.